Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001.
Authors
- Benjamin Louis Maughan (ORCID: https://orcid.org/0000-0002-0010-8551)
- Ryon P. Graf (ORCID: https://orcid.org/0000-0002-8065-4148)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Zeynep İrem Özay (ORCID: https://orcid.org/0000-0002-4827-9042)
- Gerald Li (ORCID: https://orcid.org/0000-0002-5617-6262)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Nicolas Sayegh (ORCID: https://orcid.org/0000-0003-1924-8148)
- Chadi Hage Chehade (ORCID: https://orcid.org/0009-0008-6735-5777)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Emmanuel S. Antonarakis (ORCID: https://orcid.org/0000-0003-0031-9655)
- Georges Gebrael
Institutions
- University of San Diego (US)
- University of Utah (US)
- University of Minnesota System (US)
- Huntsman Cancer Institute (US)
- GlobalFoundries (United States) (US)
- University of California San Diego (US)
- University of Minnesota Medical Center (US)
- Veterans Medical Research Foundation of San Diego (US)
- Minnesota Oncology (US)
- Foundation Medicine (United States)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1178
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09